1. Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402(10400):485-502.
2. Liu J, Pei S, Zhang P, Jiang K, Luo B, Hou Z, et al. Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma. Bmc Cancer. 2023;23(1):388.
3. Wang JY, Wang EB, Swetter SM. What Is Melanoma? Jama-J Am Med Assoc. 2023;329(11):948.
4. Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8(2):e000948.
5. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New Engl J Med. 2019;381(7):626-36.
6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-37.
7. Dimitriou F, Long GV, Menzies AM. Novel adjuvant options for cutaneous melanoma. Ann Oncol. 2021;32(7):854-65.
8. Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450-65.
9. Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.
10. Moreno AM, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology. 2019;157(3):198-209.
11. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356-71.
12. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109-18.
13. Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali D. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8(11):944-61.
14. Harris RJ, Willsmore Z, Laddach R, Crescioli S, Chauhan J, Cheung A, et al. Enriched circulating and tumor-resident TGF-beta(+) regulatory B cells in patients with melanoma promote FOXP3(+) Tregs. Oncoimmunology. 2022;11(1):2104426.
15. Correll A, Tuettenberg A, Becker C, Jonuleit H. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol. 2010;19(8):e213-21.
16. Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, et al. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022;10(5):e004605.
17. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcomes. Clin Cancer Res. 2010;16(13):3356-67.
18. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. P Natl Acad Sci Usa. 2009;106(48):20429-34.
19. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup LM, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561-5.
20. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018;175(4):984-97.
Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Lancet. 2023;402(10400):485-502.
2. Liu J, Pei S, Zhang P, Jiang K, Luo B, Hou Z, et al. Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma. Bmc Cancer. 2023;23(1):388.
3. Wang JY, Wang EB, Swetter SM. What Is Melanoma? Jama-J Am Med Assoc. 2023;329(11):948.
4. Michielin O, Atkins MB, Koon HB, Dummer R, Ascierto PA. Evolving impact of long-term survival results on metastatic melanoma treatment. J Immunother Cancer. 2020;8(2):e000948.
5. Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. New Engl J Med. 2019;381(7):626-36.
6. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-37.
7. Dimitriou F, Long GV, Menzies AM. Novel adjuvant options for cutaneous melanoma. Ann Oncol. 2021;32(7):854-65.
8. Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450-65.
9. Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.
10. Moreno AM, Li Z, DuPage M. Treg programming and therapeutic reprogramming in cancer. Immunology. 2019;157(3):198-209.
11. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16(6):356-71.
12. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109-18.
13. Shan F, Somasundaram A, Bruno TC, Workman CJ, Vignali D. Therapeutic targeting of regulatory T cells in cancer. Trends Cancer. 2022;8(11):944-61.
14. Harris RJ, Willsmore Z, Laddach R, Crescioli S, Chauhan J, Cheung A, et al. Enriched circulating and tumor-resident TGF-beta(+) regulatory B cells in patients with melanoma promote FOXP3(+) Tregs. Oncoimmunology. 2022;11(1):2104426.
15. Correll A, Tuettenberg A, Becker C, Jonuleit H. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol. 2010;19(8):e213-21.
16. Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, et al. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022;10(5):e004605.
17. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res. 2010;16(13):3356-67.
18. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. P Natl Acad Sci Usa. 2009;106(48):20429-34.
19. Cabrita R, Lauss M, Sanna A, Donia M, Skaarup LM, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561-5.
20. Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018;175(4):984-97.
21. Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2024;
22. Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088.
23. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739-40.
24. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. Bmc Bioinformatics. 2008;9:559.
25. Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenetics. 2019;11(1):123.
26. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509-14.
27. Liu J, Pei S, Zhang P, Jiang K, Luo B, Hou Z, et al. Liquid-liquid phase separation throws novel insights into treatment strategies for skin cutaneous melanoma. Bmc Cancer. 2023;23(1):388.
28. Maeser D, Gruener RF, Huang RS. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22(6):bbab260.
29. Iglesias-Escudero M, Arias-Gonzalez N, Martinez-Caceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22(1):26.
30. Chen BJ, Zhao JW, Zhang DH, Zheng AH, Wu GQ. Immunotherapy of Cancer by Targeting Regulatory T cells. Int Immunopharmacol. 2022;104:108469.
31. Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Therapeut. 2021;221:107753.
32. Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022;22(4):195-207.
33. Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH, et al. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008;26(20):3445-55.
34. Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21(7):413-30.
35. Chang S, Yim S, Park H. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. Exp Mol Med. 2019;51(6):1-17.
36. Menefee DS, McMasters A, Pan J, Li X, Xiao D, Waigel S, et al. Age-related transcriptome changes in melanoma patients with tumor-positive sentinel lymph nodes. Aging (Albany NY). 2020;12(24):24914-39.
37. Wang Q, Pan F, Li S, Huang R, Wang X, Wang S, et al. The prognostic value of the proteasome activator subunit gene family in skin cutaneous melanoma. J Cancer. 2019;10(10):2205-19.
38. Nyati KK, Zaman MM, Sharma P, Kishimoto T. Arid5a, an RNA-Binding Protein in Immune Regulation: RNA Stability, Inflammation, and Autoimmunity. Trends Immunol. 2020;41(3):255-68.
39. Kang Z, Wang J, Huang W, Liu J, Yan W. Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis. Front Cell Dev Biol. 2022;10:874429.
40. Lu Q, Cai P, Yu Y, Liu Z, Chen G, Zeng Z. Sema4D correlates with tumour immune infiltration and is a prognostic biomarker in bladder cancer, renal clear cell carcinoma, melanoma and thymoma. Autoimmunity. 2021;54(5):294-302.
41. Liu C, Li S, Tang Y. Advances in the expression and function of Fyn in different human tumors. Clin Transl Oncol. 2023;25(10):2852-60.
42. Larriba E, de Juan RC, Garcia-Martinez A, Quintanar T, Rodriguez-Lescure A, Soto JL, et al. Identification of new targets for glioblastoma therapy based on a DNA expression microarray. Comput Biol Med. 2024;179:108833.
43. Ahmed F, Khan AA, Ansari HR, Haque A. A Systems Biology and LASSO-Based Approach to Decipher the Transcriptome-Interactome Signature for Predicting Non-Small Cell Lung Cancer. Biology-Basel. 2022;11(12):1752.
44. Frost HR, Amos CI. Gene set selection via LASSO penalized regression (SLPR). Nucleic Acids Res. 2017;45(12):e114.
45. Kang J, Choi YJ, Kim IK, Lee HS, Kim H, Baik SH, et al. LASSO-Based Machine Learning Algorithm for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer. Cancer Res Treat. 2021;53(3):773-83.
46. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. Bmc Bioinformatics. 2008;9:559.
47. Horvath S, Dong J. Geometric interpretation of gene coexpression network analysis. Plos Comput Biol. 2008;4(8):e1000117.
48. Weston DJ, Gunter LE, Rogers A, Wullschleger SD. Connecting genes, coexpression modules, and molecular signatures to environmental stress phenotypes in plants. BMC Syst Biol. 2008;2:16.
49. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics. 2008;24(5):719-20.